Locus Biosciences
Locus Biosciences is a precision medicine company focused on developing engineered bacteriophage therapies to treat bacterial infections and immunology disorders. They leverage modern technologies including synthetic biology, robotics, and AI to engineer phage cocktails with payloads that are more effective than natural phages. Their mission is to revolutionize medicine by creating targeted, precision antimicrobials that address unmet medical needs and combat antibiotic resistance.
Industries
Nr. of Employees
medium (51-250)
Locus Biosciences
Morrisville, North Carolina, United States, North America
Products
Clinical-stage engineered bacteriophage therapeutic for E. coli infections (precision antimicrobial)
A precision phage-based therapeutic candidate designed to target E. coli infections; progressed into clinical development including controlled trials and registrational studies.
CRISPR-enhanced bacteriophage candidate for Pseudomonas aeruginosa (diagnostic-enabled development)
An engineered phage candidate targeting P. aeruginosa intended for use with an NGS-based companion diagnostic to support patient selection in trials.
Integrated discovery platform for engineered phage therapies
A technology stack combining automation, sequencing, synthetic biology, and AI/ML to design and select engineered phage cocktails for therapeutic development.
Clinical-stage engineered bacteriophage therapeutic for E. coli infections (precision antimicrobial)
A precision phage-based therapeutic candidate designed to target E. coli infections; progressed into clinical development including controlled trials and registrational studies.
CRISPR-enhanced bacteriophage candidate for Pseudomonas aeruginosa (diagnostic-enabled development)
An engineered phage candidate targeting P. aeruginosa intended for use with an NGS-based companion diagnostic to support patient selection in trials.
Integrated discovery platform for engineered phage therapies
A technology stack combining automation, sequencing, synthetic biology, and AI/ML to design and select engineered phage cocktails for therapeutic development.
Services
cGMP clinical biomanufacturing for phage and viral vector material
On-site manufacturing of cGMP-compliant clinical trial material, including process development, scale-up, and CMC operations.
Discovery and lead-optimization using high-throughput automation and AI
Screening and lead selection services combining robotics, sequencing, ML models, and genomic informatics to identify optimized phage cocktails.
Companion diagnostic development (NGS/metagenomics)
Collaborative development of sequencing-based diagnostics to detect target pathogens and enable diagnostic-driven patient selection.
cGMP clinical biomanufacturing for phage and viral vector material
On-site manufacturing of cGMP-compliant clinical trial material, including process development, scale-up, and CMC operations.
Discovery and lead-optimization using high-throughput automation and AI
Screening and lead selection services combining robotics, sequencing, ML models, and genomic informatics to identify optimized phage cocktails.
Companion diagnostic development (NGS/metagenomics)
Collaborative development of sequencing-based diagnostics to detect target pathogens and enable diagnostic-driven patient selection.
Expertise Areas
- Bacteriophage therapeutics
- CRISPR-based antimicrobial development
- Clinical trial management for biologics and biologic-like therapies
- GMP biomanufacturing and CMC
Key Technologies
- CRISPR-Cas nuclease-enabled antimicrobials
- Bacteriophage engineering
- High-throughput automation and robotics
- Machine learning for drug discovery